HR+   

Questions discussed in this category


Based on MINDACT update from 2020, a 5% difference in DMFS for patients 50 years or younger was noted, favoring treatment with chemotherapy (93.6%; 95...

How would your treatment change given pCR rates are reportedly much lower in triple positive patients?

For example, if a post-menopausal elderly woman has a small focus of node positive disease, would once consider adjuvant abemacicliib + endocrine ther...

Pre-menopausal women make progesterone and their menses are typically lighter on tamoxifen because it's a mild endometrial ER stimulant blocking their...

How has your practice been impacted by the ECOG 2108 (Khan et al. ASCO 2020 Abst LBA2)? Are there sites or distribution of disease that prompt you to ...

Patient had a clinical T2N0 cancer at diagnosis, completed 6 cycles TCHP, and had 0.2mm residual disease with 80% cellularity, negative sentinel node.

Do you give first line CDK 4/6 inhibitors with Tamoxifen or Aromatase Inhibitor (+/- GnRH analogue)?

She had had 4 prior biopsies. Would the fact that she received 2 months of neoadjuvant tamoxifen due to COVID change your approach?

While the KATHERINE trial for HER2+ used path staging, CREATE-X for TNBC with capecitabine used the Japanese Breast Cancer Society response criteria. ...

< 4 lymph nodes involved, initial diagnosis was 11 years ago when she was treated with mastectomy and adjuvant tamoxifen for 5 years.  

This patient underwent mastectomy and ALND (10/28 positive lymph nodes). Immediately following axillary LN dissection (and prior to radiation) imaging...

How would this change if the patient had metastatic HR+,HER2- breast cancer and now has symptomatic pancytopenia secondary to BM involvement after TCH...

ie, not a classic NTRK3-ETV6 fusion.The patient has progressed through CDk4/6 inhibitors and intolerant of alpelisib, and does not want chemotherapy.&...

She has no other site of disease progression and has been on an aromatase inhibitor (progressed in the CNS while on a study with adjuvant abemaciclib)...

In the absence of side effects, would you be inclined to continue beyond 10 years as chemoprevention? Would you factor an intermediate/high oncotype R...

Data presented at the 2017 SABCS (abstract GS1-01) of the EBCTCG meta-analysis stating a benefit of dose-dense chemotherapy applies to ER positive and...

Endocrine therapy is usually not indicated for DCIS s/p bilateral mastectomy, but would the fact that residual tissue (nipple-sparing) alter your deci...

Would you offer adjuvant chemotherapy to a post-menopausal woman with a BRCA2 mutation and a T2N0 ER positive breast cancer with an oncotype of 12?

It is included in favorable histologies on NCCN, but no mention of how to treat based off HER2 status.

She had disease progression on palbociclib and letrozole. She also has a PIK3CA mutation however did not tolerate alpelisib due to Grade 3 hyperglycem...

Margins were negative and there was no evidence of LCIS or lobular component in the lumpectomy specimen. Role for possible mastectomy?    ...

More generally, do absorption issues effect the efficacy of tamoxifen and/or aromatase inhibitors?

Prior localized HR+,HER2- breast cancer treated with adjuvant AC-T (5years ago) Recent ipsilateral axillary recurrence (HR-,HER2+) s/p neoadjuvant TC...

Would you consider an aggressive approach with RT and/or surgery to the bone lesion and treat the primary as locally advanced breast cancer?

Clinical T1c patients were included in the KATHERINE trial that often are treated with adjuvant paclitaxel and trastuzumab

One such patient progressed through trastuzumab/pertuzumab/letrozole and TDM1 alone.  How would you combine ER+ approaches (eg CDK 4/6 inhibitor ...

For example first-line ribociclib/letrozole, and second-line palbociclib/fulvestrant?  Without data, would there be any expected benefit?

There is a gray area in clinical decision making where the practice seems to be different for borderline size tumors such as a 7 mm lesion with no oth...

Do you have a cutoff in terms of tumor size, number of LN, Oncotype score, etc that makes you choose lower vs higher intensity chemo?

Assume good compliance with oral therapy, equivalent access to either agent, no contraindictions to either therapy, and absence of any visceral crisis...


Papers discussed in this category


Lancet (London, England), 2016-12-17

Breast cancer research and treatment, 2014-01

Lancet (London, England), 2013-03-09

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008-04-20

Journal of the National Cancer Institute, 2013-07-17

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-09-01

The New England journal of medicine, 2016-07-21

The New England journal of medicine, 2018-07-12

Mol Oncol,

JAMA,

N Engl J Med, 2015 Jan 8

Lancet Oncol., 2017 Feb 24

Eur. J. Cancer, 2017 May 03

The New England journal of medicine, 2012-01-12

The New England journal of medicine, 2016-08-25

Journal of the National Comprehensive Cancer Network : JNCCN, 2017-04

Breast cancer research and treatment, 2018-06

The New England journal of medicine, 2019-02-14

Oncotarget,

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-04-10

The Lancet. Oncology, 2014-02

Annals of surgical oncology, 2018-10

Annals of surgery, 2019-03

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-08-01

N Engl J Med, 2011 Oct 6

N. Engl. J. Med., 2017-07-13

Lancet (London, England), 2012-02-04

Breast cancer research and treatment, 2008-01

Cancer, 1998-02-15

Cancer, 2010-04-15

Journal of the National Cancer Institute, 2005-09-07

The Lancet. Oncology, 2019-01

N. Engl. J. Med.,

Breast cancer research and treatment, 2011-07

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006-05-01

N Engl J Med, 2005 Jun 2

Cancer, 2016-04-15

The New England journal of medicine, 2019-06-20

Ann. Oncol.,

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2017-09

Springerplus, 2016 May 10

JAMA dermatology, 2018-06-01

The New England journal of medicine, 2014-07-10

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-05-10

N. Engl. J. Med.,

The American journal of surgical pathology, 2017-11

N. Engl. J. Med.,

Oncologist, 2020 Jul 03

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003-11-15

N. Engl. J. Med., 2017 Jun 04

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006-08-10

JAMA Oncol, 2019 Sep 30

J. Clin. Oncol., 2019 Jul 24

Anticancer Res.,

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-07-01

The New England journal of medicine, 2018-07-12

Lancet Oncol., 2018 Nov 06

J. Clin. Oncol., 2019 Oct 16

Breast Cancer Res. Treat., 2006 May 11

Lancet Oncol., 2009 Nov 10

Breast cancer research and treatment, 2014-11

The Lancet. Oncology, 2016-03

Mol Clin Oncol, 2019 Nov 29

Clin. Cancer Res., 2019 Oct 24

Cancer Treat. Rev., 2012 Nov 28

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-04-01

Cancer, 2016-12-01

N. Engl. J. Med.,

The New England journal of medicine, 2012-11-08

Lancet Oncol., 2020 Mar 12

J. Clin. Oncol., 2009 Sep 28

Journal of the National Cancer Institute, 2005-11-16

J. Clin. Oncol., 2020 Sep 20

Cancer, 2020 Jun 10

Journal of the National Cancer Institute, 1997-11-19

Journal of surgical oncology, 2017-06

Breast cancer research and treatment, 2015-11

Breast Cancer Res Treat, 2020 May 20

Lancet Oncol., 2014-06-01

The Lancet. Oncology, 2018-04

Pathol Oncol Res, 2017 Sep 11

J Clin Oncol, 2020 Jan 13